248 related articles for article (PubMed ID: 35008570)
21. Immunotherapy for melanoma.
Cuevas LM; Daud AI
Semin Cutan Med Surg; 2018 Jun; 37(2):127-131. PubMed ID: 30040090
[TBL] [Abstract][Full Text] [Related]
22. The window of opportunities for targeted therapy in BRAFwt/NRASwt/KITwt melanoma: biology and clinical implications of fusion proteins and other mutations.
Berger M; Richtig G; Kashofer K; Aigelsreiter A; Richtig E
G Ital Dermatol Venereol; 2018 Jun; 153(3):349-360. PubMed ID: 29600692
[TBL] [Abstract][Full Text] [Related]
23. Recent advances in therapeutic strategies for unresectable or metastatic melanoma and real-world data in Japan.
Uhara H
Int J Clin Oncol; 2019 Dec; 24(12):1508-1514. PubMed ID: 29470725
[TBL] [Abstract][Full Text] [Related]
24. Principles of Targeted Therapy for Melanoma.
Sun J; Carr MJ; Khushalani NI
Surg Clin North Am; 2020 Feb; 100(1):175-188. PubMed ID: 31753111
[TBL] [Abstract][Full Text] [Related]
25. Immune consequences of kinase inhibitors in development, undergoing clinical trials and in current use in melanoma treatment.
Vella LJ; Andrews MC; Behren A; Cebon J; Woods K
Expert Rev Clin Immunol; 2014 Aug; 10(8):1107-23. PubMed ID: 24939732
[TBL] [Abstract][Full Text] [Related]
26. Update on systemic therapy for advanced cutaneous melanoma and recent development of novel drugs.
Swe T; Kim KB
Clin Exp Metastasis; 2018 Aug; 35(5-6):503-520. PubMed ID: 30019239
[TBL] [Abstract][Full Text] [Related]
27. Emerging targeted therapies for melanoma.
Johnson DB; Pollack MH; Sosman JA
Expert Opin Emerg Drugs; 2016 Jun; 21(2):195-207. PubMed ID: 27148822
[TBL] [Abstract][Full Text] [Related]
28. The biology and therapeutic management of melanoma brain metastases.
Abate-Daga D; Ramello MC; Smalley I; Forsyth PA; Smalley KSM
Biochem Pharmacol; 2018 Jul; 153():35-45. PubMed ID: 29278675
[TBL] [Abstract][Full Text] [Related]
29. Targeted therapy and immunotherapy: Emerging biomarkers in metastatic melanoma.
LoRusso PM; Schalper K; Sosman J
Pigment Cell Melanoma Res; 2020 May; 33(3):390-402. PubMed ID: 31705737
[TBL] [Abstract][Full Text] [Related]
30. First line treatment of BRAF mutated advanced melanoma: Does one size fit all?
Giugliano F; Crimini E; Tarantino P; Zagami P; Uliano J; Corti C; Trapani D; Curigliano G; Ascierto PA
Cancer Treat Rev; 2021 Sep; 99():102253. PubMed ID: 34186441
[TBL] [Abstract][Full Text] [Related]
31. The Role of BRAF-Targeted Therapy for Advanced Melanoma in the Immunotherapy Era.
Vanella V; Festino L; Trojaniello C; Vitale MG; Sorrentino A; Paone M; Ascierto PA
Curr Oncol Rep; 2019 Jul; 21(9):76. PubMed ID: 31359162
[TBL] [Abstract][Full Text] [Related]
32. Melanoma immunotherapy: strategies to overcome pharmacological resistance.
Trojaniello C; Vitale MG; Scarpato L; Esposito A; Ascierto PA
Expert Rev Anticancer Ther; 2020 Apr; 20(4):289-304. PubMed ID: 32195606
[No Abstract] [Full Text] [Related]
33. Meta-Analysis and Systematic Review of the Genomics of Mucosal Melanoma.
Broit N; Johansson PA; Rodgers CB; Walpole ST; Newell F; Hayward NK; Pritchard AL
Mol Cancer Res; 2021 Jun; 19(6):991-1004. PubMed ID: 33707307
[TBL] [Abstract][Full Text] [Related]
34. Molecular genetic and immunotherapeutic targets in metastatic melanoma.
Melis C; Rogiers A; Bechter O; van den Oord JJ
Virchows Arch; 2017 Aug; 471(2):281-293. PubMed ID: 28357489
[TBL] [Abstract][Full Text] [Related]
35. Novel Targets for the Treatment of Melanoma.
Ambrosi L; Khan S; Carvajal RD; Yang J
Curr Oncol Rep; 2019 Nov; 21(11):97. PubMed ID: 31696329
[TBL] [Abstract][Full Text] [Related]
36. Combination of targeted therapy and immunotherapy in melanoma.
Blank CU; Hooijkaas AI; Haanen JB; Schumacher TN
Cancer Immunol Immunother; 2011 Oct; 60(10):1359-71. PubMed ID: 21847631
[TBL] [Abstract][Full Text] [Related]
37. Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017.
Ugurel S; Röhmel J; Ascierto PA; Flaherty KT; Grob JJ; Hauschild A; Larkin J; Long GV; Lorigan P; McArthur GA; Ribas A; Robert C; Schadendorf D; Garbe C
Eur J Cancer; 2017 Sep; 83():247-257. PubMed ID: 28756137
[TBL] [Abstract][Full Text] [Related]
38. Interface of signal transduction inhibition and immunotherapy in melanoma.
Shada AL; Molhoek KR; Slingluff CL
Cancer J; 2010; 16(4):360-6. PubMed ID: 20693848
[TBL] [Abstract][Full Text] [Related]
39. The combination of stereotactic radiosurgery with immune checkpoint inhibition or targeted therapy in melanoma patients with brain metastases: a retrospective study.
Martins F; Schiappacasse L; Levivier M; Tuleasca C; Cuendet MA; Aedo-Lopez V; Gautron Moura B; Homicsko K; Bettini A; Berthod G; Gérard CL; Wicky A; Bourhis J; Michielin O
J Neurooncol; 2020 Jan; 146(1):181-193. PubMed ID: 31836957
[TBL] [Abstract][Full Text] [Related]
40. Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma.
Yu J; Yan J; Guo Q; Chi Z; Tang B; Zheng B; Yu J; Yin T; Cheng Z; Wu X; Yu H; Dai J; Sheng X; Si L; Cui C; Bai X; Mao L; Lian B; Wang X; Yan X; Li S; Zhou L; Flaherty KT; Guo J; Kong Y
Clin Cancer Res; 2019 Nov; 25(21):6511-6523. PubMed ID: 31375512
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]